摘要
目的：探讨重组人干扰素联合阿昔洛韦治疗流行性腮腺炎的临床疗效及安全性。方法：将2012年1月至2012年12月本科收治的流行性腮腺炎患者,共48例;对照组17例及观察组31例。对照组按常规方法治疗,清开灵及阿昔洛韦注射液联合治疗,清开灵注射液用量为0.6ml（/kg·d）,以5%葡萄糖液稀释后静点,阿昔洛韦用量为10mg（/kg·d）,以5%葡萄糖液稀释后静点。观察组在此基础上给予重组人干扰素6~12U皮下注射,1次/d。结果：观察组总有效率明显高于对照组（P均〈0.05）;临床症状及体征消失时间明显短于对照组（P均〈0.05）。结论：重组人干扰素联合阿昔洛韦治疗流行性腮腺炎疗效确切,安全可靠,值得临床借鉴。
Objective： To investigate the clinical effectiveness and safety of treatment for patients with mumps by combination of recombinant human interferon itnd acyclovir. Methods： From Jan 2012 to Dec 2012 in our hospital,48 patients with mumps were divided into control group（n=17） and observation group（n=31 ） in which control group were given conventional therapy of Qingkailing injection[ 0.6ml/ （kg· d）, by 5%GS intravenous injection ] combined with acyclovir injection [ 10mg/（kg·d）, by 5%GS intravenous injection ], and observation group were extra given human recombinant interferon（6-12U,subcutaneous injection, l/d） on the basis of conventional therapy. Results：The total effective rate in observation group was higher than that of control group（P〈0.05）,clinical symptoms and signs disappeared time were significantly shorter than that of the control group （P〈0. 05）. Conclusion： The treatment for patients with mumps by combination of recombinant human interferon and acyclovir is definite effect, safe and reliable, which is worth of clinical reference.
出处
《甘肃医药》
2013年第8期566-567,共2页
Gansu Medical Journal
